231 related articles for article (PubMed ID: 17301509)
21. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
Ademi Z; Zomer E; Tonkin A; Liew D
Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
[TBL] [Abstract][Full Text] [Related]
23. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
24. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
[TBL] [Abstract][Full Text] [Related]
26. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
Claes C; Mittendorf T; Grond M; von der Schulenburg JM
Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
28. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
29. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2006; 24(7):709-26. PubMed ID: 16802846
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
31. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men.
Pignone M; Earnshaw S; McDade C; Pletcher MJ
J Gen Intern Med; 2013 Nov; 28(11):1483-91. PubMed ID: 23681842
[TBL] [Abstract][Full Text] [Related]
32. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
Lamotte M; Annemans L; Kawalec P; Zoellners Y
Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
[TBL] [Abstract][Full Text] [Related]
33. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
[TBL] [Abstract][Full Text] [Related]
34. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
35. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
[TBL] [Abstract][Full Text] [Related]
36. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
Annemans L; Wittrup-Jensen K; Bueno H
J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
[TBL] [Abstract][Full Text] [Related]
37. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
38. Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.
Hori M; Ikeda S; Okumura K; Matsuda S; Koretsune Y; Montouchet C; Watanabe-Fujinuma E; Evers T; Rossi B; Ruff L; Briere JB
J Med Econ; 2016 Sep; 19(9):889-99. PubMed ID: 27112188
[TBL] [Abstract][Full Text] [Related]
39. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
Hassan C; Rex DK; Cooper GS; Zullo A; Launois R; Benamouzig R
Gut; 2012 Aug; 61(8):1172-9. PubMed ID: 21997545
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
